Cargando…
Cost of AF Ablation: Where Do We Stand?
Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, a...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051175/ https://www.ncbi.nlm.nih.gov/pubmed/21403880 http://dx.doi.org/10.4061/2011/589781 |
_version_ | 1782199451147829248 |
---|---|
author | Khaykin, Yaariv Shamiss, Yana |
author_facet | Khaykin, Yaariv Shamiss, Yana |
author_sort | Khaykin, Yaariv |
collection | PubMed |
description | Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among symptomatic AF patients. The purpose of this paper is to describe the evidence on the financial implications related to ablation based on published data and authors' experience. |
format | Text |
id | pubmed-3051175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-30511752011-03-14 Cost of AF Ablation: Where Do We Stand? Khaykin, Yaariv Shamiss, Yana Cardiol Res Pract Review Article Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among symptomatic AF patients. The purpose of this paper is to describe the evidence on the financial implications related to ablation based on published data and authors' experience. SAGE-Hindawi Access to Research 2011-03-03 /pmc/articles/PMC3051175/ /pubmed/21403880 http://dx.doi.org/10.4061/2011/589781 Text en Copyright © 2011 Y. Khaykin and Y. Shamiss. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Khaykin, Yaariv Shamiss, Yana Cost of AF Ablation: Where Do We Stand? |
title | Cost of AF Ablation: Where Do We Stand? |
title_full | Cost of AF Ablation: Where Do We Stand? |
title_fullStr | Cost of AF Ablation: Where Do We Stand? |
title_full_unstemmed | Cost of AF Ablation: Where Do We Stand? |
title_short | Cost of AF Ablation: Where Do We Stand? |
title_sort | cost of af ablation: where do we stand? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051175/ https://www.ncbi.nlm.nih.gov/pubmed/21403880 http://dx.doi.org/10.4061/2011/589781 |
work_keys_str_mv | AT khaykinyaariv costofafablationwheredowestand AT shamissyana costofafablationwheredowestand |